RMi Pre-opening: Day #3, JP Morgan healthcare Conference

January 14, 2026 8:30am

The hang-overs are as bad as access to some meetings and break-out rooms

While earnings season begins as a dud and more econs i.e., inflation data adds to the uncertainty

Pre-open Signals: 2 Positive and 1 Negative with many non-pre-open indications; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

Tuesday’s RMi Closing Bell: JP Morgan healthcare Conference meetings-on … https://www.regmedinvestors.com/articles/14266   

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249       

Wednesday: The pre-open Dow futures are DOWN -0.28% or (-133 points), the S&P futures are DOWN -0.39% or (-27 points) and the Nasdaq futures are DOWN -0.51% or (-131 points)

• U.S. stock futures are floating lower, Wednesday, 1/14
• European markets experience some record highs,
• Asia Pacific markets traded mixed as Japan walked the high wire

Economic Data:

• 8:30 am              U.S. retail sales (delayed report) Nov.                      0.4%      0.0%
• 8:30 am                Retail sales minus autos (delayed report)              Nov.                      0.3%      0.4%
• 8:30 am                U.S. Producer price index (delayed report)           Nov.                      0.3%      **0.3%
• 8:30 am                Core PPI (delayed report)             Nov.                      --             **0.1%
• 8:30 am                PPI year over year            Nov.                      --             2.7%
• 8:30 am                Core PPI year over year Nov.                      --             2.9%
• 10:00 am             U.S. Business inventories (delayed report)            Oct.                        0.2%      0.2%
• 10:00 am             Existing home sales         Dec.                       4.22 million         4.13 million
• 12:00 pm             Atlanta Fed President Raphael Bostic speaks                                                       
• 12:30 pm             Fed Governor Stephen Miran speaks                                                      
• 11:00 am             Minneapolis Fed President Neel Kashkari speaks                                               
• 2:00 pm               Federal Reserve’s Beige Book

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

• Tuesday: The Dow closed DOWN -398.21 points or -0.80%, the S&P closed DOWN -13.53 points or -0.19% while the Nasdaq closed DOWN -24.032 points or -0.10%
• Monday: The Dow closed UP +86.13 points or +0.17%, the S&P closed UP +10.99 points or +0.16% while the Nasdaq closed UP +62,558 points or +0.26%
• Friday: The Dow closed UP +237,96 points or +0.48%, the S&P closed UP +44.82 points or +0.65% while the Nasdaq closed UP +191.331 points or +0.82%
• Thursday: The Dow closed UP +270.03 points or +0.55%, the S&P closed UP +0.53 points or +0.01% while the Nasdaq closed DOWN -104.259 points or -0.44%
• Last Wednesday: The Dow closed DOWN -466.00 points or -0.94%, the S&P closed DOWN -23.89 points or -0.34% while the Nasdaq closed UP +37.102 points or +0.16%

• Last week: The S&P 500 was up +1.6%, the Dow +2.3% and the Nasdaq was up +1.9%.

• The previous week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.

• December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

Q1/26 – Q1 – 1 holiday, 2 neutral, 3 negative and 3 positive closes  

Q4 – December,

• 1 holiday, 8 positive and 12 negative closes
• November, 1 holiday, 8 positive and 11 negative sessions
• October, 1 neutral, 10 positive and 12 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Beam Therapeutics (BEAM) closed up +$0.86 after Monday’s +$6.14 with a positive +$0.30 or +0.87% pre-open

BioNTech (BNTX) closed up +$5.01 after Monday’s +$2.33 after Friday’s +$1.00 with a positive +$2.20 or +2.05% pre-open

Capricor Therapeutics (CAPR) closed up +$0.28 after Monday’s +$0.67 after Friday’s closed down -$0.78 with a negative -$0.24 or -0.97% pre-open indication

• As CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!

• I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
• Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
• CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
• It has begun; timing will be everything!
• The higher CAPR rises, the steeper the fall!

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, ****financings**** and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Welcome to my world of defining the “grey’ in our universe!

• I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
• if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

• after a surprise drop in inflation and lukewarm labor market data left betting on possible 2026 interest-rate cuts

January – 3nd week:

• 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
• 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January – 2nd week’s session

• 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
• 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
• 1/7 – Wednesday closed positive with 33 incliners, 5 decliners and 2 flats
• 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
• 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

First week:

• 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
• 1/1 -Thursday was a holiday, New Years Day

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in past session:   

• Wednesday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and IQVIA Holdings (IQV),
• Tuesday: Vertex (VRTX), Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR)
• Monday: IQVIA Holdings (IQV), BioLife Solutions (BLFS), and Vericel (VCEL)

The worst three (3) in past session:

• Wednesday: Arrowhead Pharmaceuticals (ARWR), BioLife Solutions (BLFS) and LENZ Therapeutics (LENZ)
• Tuesday: AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Entrada Therapeutics (TRDA)
• Monday: Capricor Therapeutics (CAPR), Vertex (VRTX) and Arrowhead Pharmaceuticals (ARWR)

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.